On the surface stocks just seem to be trading calmly in a trading range. Under the surface things are setting up for continuation of the bear market which is why…

Read more...

Shares of oncology-focused biotechnology company Sonnet BioTherapeutics (SONN) have plummeted more than 70% in price year-to-date due to its poor financials and the broad-based market sell-off. However, the company is…

Read more...

A tight supply has turned hedge funds bullish on crude oil. Moreover, with winter approaching and the EU embargo on Russian energy exports expected to kick in soon, oil prices…

Read more...

The stock market continues to be a challenging environment with rising rates a potent headwind. So far, the economy has been stable enough so that earnings growth has not contracted,…

Read more...

Shares of communication services company Twilio (TWLO) have plunged more than 80% in price year-to-date due to deteriorating financials and broader market weakness. Renowned investor Cathie Wood has recently gone…

Read more...

The Fed is expected to continue raising rates, for the time being, keeping the stock market under pressure. The interest rate-sensitive and tech-heavy Nasdaq composite has lost more than 30%…

Read more...

After a series of consecutive aggressive rate hikes, the labor market shows some signs of cooling. Consequently, the Fed is expected to lower its hike pace. Moreover, as investors look…

Read more...

Biopharmaceutical giant Gilead Sciences (GILD) reported better-than-expected third-quarter earnings and sales and raised its full-year guidance. Analysts see immense growth potential in the company’s HIV and oncology franchises, which should…

Read more...

The S&P 500 (SPY) may be in bear market territory, but that doesn’t mean that every stock is down. In fact, there are 3 really good reasons why Casey’s General…

Read more...

Last week, we talked about how it felt like deja vu as the S&P 500 (SPY) embarked on its 3rd bear market rally of the year. Well, today it feels…

Read more...